weekend biotech lab & lounge 27th july 2013, page-19

"PBT and PRR both had big gains again on the NASDAQ overnight and look to be breaking out. Both will get plenty of attention on the ASX on monday. NASDAQ dual listed stocks appear to have a big advantage during the current Biotech bull market. Maybe that's the way to play Biotechs by just buying a few dual NASDAQ listed stocks ???


It's a tough call and often one misconstrued, the value for any company still always remains with it's performance based on home exchange or where the majority of stock is held and traded. NASDAQ listing however gives great exposure for companies as it then falls under assessment of major funds and broking houses. The thing that always has to be taken into account with any performance on other exchanges, rises / falls in price is the volume attributed and $ value of performance. Don't forget these are all fairly expensive to initialy list and have market makers on price.


Prima with PBMD's move on Friday was pretty much insignificant with <$100K worth of stock traded and equal to <10% of the value traded on the ASX Friday.

PBT on the other hand that was some serious business with value of PRAN turnover recently.


FWIW I have interests in both of the above stocks